EZH2 and glioblastoma: A Phase II trial (NCT04771461) in newly diagnosed GBM patients with high EZH2 expression found that tazemetostat plus radiotherapy improved 12-month progression-free survival to 45% (vs 28% for standard therapy) (Gounder et al., 2020).